75 related articles for article (PubMed ID: 1802748)
1. High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location.
Del Zompo M; Piccardi MP; Ruiu S; Corsini GU; Vaccari A
Eur J Pharmacol; 1991 Sep; 202(2):293-4. PubMed ID: 1802748
[No Abstract] [Full Text] [Related]
2. The relative abilities of MPTP and MPP+ to compete with [3H]dopamine for the rat and marmoset striatal dopamine uptake site.
Barnes NM; Cheng CH; Costall B; Naylor RJ
Biochem Pharmacol; 1990 Feb; 39(4):809-11. PubMed ID: 2306287
[No Abstract] [Full Text] [Related]
3. Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes.
Del Zompo M; Piccardi MP; Ruiu S; Corsini GU; Vaccari A
Brain Res; 1992 Feb; 571(2):354-7. PubMed ID: 1611504
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
Castagnoli K; Palmer S; Castagnoli N
Neurobiology (Bp); 1999; 7(2):135-49. PubMed ID: 10591048
[TBL] [Abstract][Full Text] [Related]
5. Methamphetamine protects against MPTP neurotoxicity in C57BL mice.
Sziráki I; Kardos V; Patthy M; Pátfalusi M; Budai G
Eur J Pharmacol; 1994 Jan; 251(2-3):311-4. PubMed ID: 8149986
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
7. Acute Restraint Stress Augments 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurotoxicity via Increased Toxin Uptake into the Brain in C57BL/6 Mice.
Mitsumoto Y; Mori A
Neurosci Bull; 2018 Oct; 34(5):849-853. PubMed ID: 29987518
[TBL] [Abstract][Full Text] [Related]
8. Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
Melamed E; Youdim MB
Br J Pharmacol; 1985 Nov; 86(3):529-31. PubMed ID: 3877535
[TBL] [Abstract][Full Text] [Related]
9. Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine.
Vaccari A; Del Zompo M; Melis F; Gessa GL; Rossetti ZL
Br J Pharmacol; 1991 Nov; 104(3):573-4. PubMed ID: 1797320
[TBL] [Abstract][Full Text] [Related]
10. Differential interaction of 1-methyl-4-phenylpyridinium ion with the putatively vesicular binding site of [3H]tyramine in dopaminergic and nondopaminergic brain regions.
Vaccari A; Saba PL; Gessa GL; Del Zompo M
J Neurochem; 1993 Feb; 60(2):758-60. PubMed ID: 8419550
[TBL] [Abstract][Full Text] [Related]
11. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.
Irwin I; Finnegan KT; Delanney LE; Di Monte D; Langston JW
Brain Res; 1992 Feb; 572(1-2):224-31. PubMed ID: 1611516
[TBL] [Abstract][Full Text] [Related]
12. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
13. Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sershen H; Reith ME; Hashim A; Lajtha A
Eur J Pharmacol; 1984 Jun; 102(1):175-8. PubMed ID: 6332738
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of uptake of 1-methyl-4-phenylpyridinium ion and dopamine in striatal synaptosomes by tobacco smoke components.
Carr LA; Basham JK; York BK; Rowell PP
Eur J Pharmacol; 1992 May; 215(2-3):285-7. PubMed ID: 1396992
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
[TBL] [Abstract][Full Text] [Related]
16. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Staal RG; Yang JM; Hait WN; Sonsalla PK
Brain Res; 2001 Aug; 910(1-2):116-25. PubMed ID: 11489261
[TBL] [Abstract][Full Text] [Related]
17. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Andersen JK; Frim DM; Isacson O; Beal MF; Breakefield XO
Brain Res; 1994 Sep; 656(1):108-14. PubMed ID: 7804823
[TBL] [Abstract][Full Text] [Related]
18. Carrier-mediated efflux of [3H]dopamine and [3H]1-methyl-4-phenylpyridine: effect of ascorbic acid.
Debler EA; Sershen H; Hashim A; Lajtha A; Reith ME
Synapse; 1991 Feb; 7(2):99-105. PubMed ID: 2011830
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in preparations of rat brain.
Markstein R; Lahaye D
Eur J Pharmacol; 1984 Nov; 106(2):301-11. PubMed ID: 6335691
[TBL] [Abstract][Full Text] [Related]
20. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes.
Di Monte DA; Wu EY; Irwin I; Delanney LE; Langston JW
Glia; 1992; 5(1):48-55. PubMed ID: 1311704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
